Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New drug IPG1094 gets first human test in china

NCT ID NCT07679113

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 01, 2026 · Last updated Aug 11, 2026 · Updated 3 times

Summary

This phase 1 trial tests the drug IPG1094 in 24 healthy Chinese adults to understand how the body absorbs, processes, and eliminates it. Part A examines whether food affects a single dose, while Part B looks at repeated dosing over 10 days. All participants are monitored for safety and side effects.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
IPG1094
What this could lead to
If successful, this study will provide key data on how IPG1094 behaves in the body, supporting future trials for potential therapeutic uses.
What could go wrong
This is an early phase 1 trial in only 24 healthy volunteers, so results may not predict effects in patients. The drug may cause side effects or fail in later studies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

About 24 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2026

Expected to finish

Jan 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 50 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Male and female healthy Chinese participants aged 18 to 50 years (inclusive). 2. Comprehensive assessments including physical examination, vital signs, 12-lead ECG, chest X-ray and laboratory tests are normal or with abnormalities judged not clinically significant by the investigator. 3. Body weight: Male ≥50.0 kg, Female ≥45.0 kg; Body Mass Index (BMI) ranges from 19.0 to 26.0 (inclusive). BMI = Weight(kg) / Height(m)². 4. Female participants are non-pregnant and non-lactating. 5. Participants have no pregnancy plan and no sperm/egg donation plan from 2 weeks before screening to 6 months after the end of the study, and agree to use effective contraception during this period. 6. Voluntarily sign the written informed consent form, and fully understand the trial content and potential adverse reactions. Exclusion Criteria: 1. History of severe cardiovascular, respiratory, hepatic, renal, gastrointestinal, neurological, psychiatric or other systemic diseases with clinical significance. 2. QTcF interval \>450 ms (male) or \>470 ms (female). 3. History of recurrent headache, nausea or vomiting. 4. Blood loss ≥400 mL within 3 months before screening, or plan to donate blood during the study. 5. History of orthostatic hypotension or dysphagia. 6. History of gastrointestinal diseases affecting drug absorption. 7. Lactose intolerance, special dietary restrictions, or unable to follow unified diet requirements during the trial. 8. History of drug/food allergy, drug abuse or alcohol abuse. 9. Heavy smoking, excessive intake of tea, coffee or caffeinated beverages within 3 months before screening. 10. Use of any prescription drugs, over-the-counter drugs, health products or Chinese herbal medicines within 14 days before screening. 11. Use of drugs affecting liver metabolism or gastrointestinal environment within 30 days before screening. 12. Intake of citrus fruits/juices within 5 days before screening or during the trial. 13. Participated in other clinical trials within 3 months before screening. 14. Positive result of urine drug screen or breath alcohol test at admission. 15. Difficulty in venous blood collection, history of syncope during blood collection. 16. Acute illness before screening, or other conditions judged inappropriate for participation by the investigator.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Healthy volunteers are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Shanghai Xuhui Central Hospital

    RECRUITING

    Shanghai, Xuhui, 200031, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.